A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Neoplasms, Advanced Solid

Interventions

DRUG

Trebananib 3 mg/kg

Trebananib (AMG 386) 3 mg/kg, intravenous infusion.

DRUG

Trebananib 10 mg/kg

Trebananib (AMG 386) 10 mg/kg, intravenous infusion.

DRUG

Trebananib 30 mg/kg

Trebananib (AMG 386) 30 mg/kg, intravenous infusion.